The CDMO has invested in its clinical services and diagnostic service capabilities
Almac Group, the global contract pharmaceutical development and manufacturing organisation, has invested in its Durham, North Carolina Clinical Services’ and Diagnostic Services’ capabilities with the opening of a 24,000 ft2 building.
As part of Almac’s ongoing growth strategy, this significant expansion adds a fourth building to the Durham campus and provides additional office space for more than 100 new employees in the next 3 years.
This additional capacity complements Almac’s existing Durham facility, which offers a range of end-to-end clinical trial supply solutions to clients globally, as well as Almac Diagnostic Services to provide biomarker driven clinical trial solutions.
Donna Christopher, Global VP of Operations, Almac Clinical Services, said: “Almac’s exceptional quality is demonstrated by our dedicated employees, all of whom work hard to strengthen relationships for long-term collaboration.”
"We are delighted that this further investment in our Durham facilities enables us to continue to support our clients’ needs and meet the increased demands for our integrated services. This expansion not only provides us with a stronger ability to service our growing customer base but it also serves to demonstrate our commitment to being the most trusted and stable name in the clinical supply marketplace.”
This expansion of service capacity comes shortly after the conclusion of Almac’s previous $5.2 million investment at the North Carolina facility in 2016, which saw the expansion of its Clinical Services operations along with the development of its Diagnostics and Clinical Technologies services.